Loss of function polymorphisms in TLR4 or P2RX7 fail to impact clinical outcome in patients with non-small cell lung cancer, suggesting that tumor biology, chemotherapeutic agent, or both may influence whether tumor cell death is immunogenic, and which cell death pathway is activated. Here, TLR4 is linked to neoplasm.